- ManufacturersPrevents compliance costs for manufacturers and importers of products containing DecaBDE and PIP(3:1).
- Potential benefitPreserves jobs in affected manufacturing and downstream sectors by avoiding new regulatory compliance.
- Potential benefitReduces regulatory burden and paperwork for companies handling these chemicals.
Disapprove EPA Decabromodiphenyl Ether and Phenol, Isopropylated Phosphate (3:1…
Referred to the House Committee on Energy and Commerce.
This joint resolution seeks congressional disapproval, under the Congressional Review Act, of an Environmental Protection Agency rule titled “Decabromodiphenyl Ether and Phenol, Isopropylated Phosphate (3:1); Revision to the Regulation of Persistent, Bioaccumulative, and Toxic Chemicals Under the Toxic Substances Control Act (TSCA).” If enacted, the resolution would nullify the EPA rule (89 Fed. Reg. 91486, Nov. 19, 2024) and prevent the agency from issuing the same rule in substantially identical form.
Progressives emphasize health and environmental protection losses.
Narrow CRA vehicle is procedurally simple and common in House; outcome depends on majority alignment with deregulatory aim.
This joint resolution seeks congressional disapproval, under the Congressional Review Act, of an Environmental Protection Agency rule titled “Decabromodiphenyl Ether and Phenol, Isopropylated Phosphate (3:1); Revision to the Regulation of Persistent, Bioaccumulative, and Toxic Chemicals Under the Toxic Substances Control Act (TSCA).” If enacted, the resolution would nullify the EPA rule (89 Fed.
Reg. 91486, Nov. 19, 2024) and prevent the agency from issuing the same rule in substantially identical form.
The measure was referred to the House Committee on Energy and Commerce.
Simple statutory mechanism but politically charged regulatory rollback; must clear both chambers and be signed, increasing hurdles.
How solid the drafting looks.
Progressives emphasize health and environmental protection losses.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenContinues potential environmental and human exposure to persistent, bioaccumulative toxic chemicals.
- Potential burdenShifts potential cleanup and public health costs to governments and affected communities.
- Potential burdenLimits EPA's ability to regulate chemical risks under TSCA and address emerging hazards.
Why the argument around this bill splits.
Progressives emphasize health and environmental protection losses.
Likely opposed: views disapproval as a rollback of chemical safety protections and EPA authority.
Sees the resolution as harmful to public health, environmental justice, and communities exposed to persistent toxic chemicals.
Mixed view: wants to balance chemical safety with economic impacts and rulemaking quality.
Would evaluate scientific basis, cost-benefit analysis, and administrative procedure before taking a firm position.
Likely supportive: views disapproval as curbing EPA overreach and preventing costly, burdensome federal regulation.
Emphasizes economic and federalism arguments and skepticism of aggressive administrative rulemaking.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Simple statutory mechanism but politically charged regulatory rollback; must clear both chambers and be signed, increasing hurdles.
- Which congressional majority supports deregulatory CRA use
- Level of industry or environmental stakeholder mobilization
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives emphasize health and environmental protection losses.
Simple statutory mechanism but politically charged regulatory rollback; must clear both chambers and be signed, increasing hurdles.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Disapprove EPA Decabromodiphenyl Ether and Phenol, Isopropylat…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.